Scientific Publications

Legend Biotech sponsors research with academic institutions to evaluate our agents. The manuscripts from this research are presented below.

Year :

Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma

Sundar Jagannath, Thomas G Martin, Yi Lin, Adam D Cohen, Noopur Raje, Myo Htut, Abhinav Deol, Mounzer Agha, Jesus G Berdeja, Alexander M Lesokhin, Jessica J Liegel, Adriana Rossi, Alex Lieberman-Cribbin, Saad Z Usmani, Binod Dhakal, Samir Parekh, Hui Li, Feng Wang, Rocio Montes de Oca, Vicki Plaks, Huabin Sun, Arnob Banerjee, Jordan M Schecter, […]

Real-World Treatment Patterns and Outcomes in Patients With Lenalidomide-Refractory Multiple Myeloma With 1 to 3 Prior Lines: SEER-Medicare Database

Binod Dhakal, Jinghua He, Jordan M Schecter, William Deraedt, Ana Slaughter, Carolina Lonardi, Sandhya Nair, Jianming He, Seina Lee, Patricia Cost, Nitin Patel, Mythili Koneru, Hermann Einsele

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison

Noemi Puig, Joris Diels, Suzy van Sanden, João Mendes,Heather Burnett, Allie Cichewicz, Seina Lee, Teresa Hernando, Jordan M Schecter, Nikoletta Lendvai, Nitin Patel, José María Sanchez-Pina, Serena Rocchi, Roberto Mina, Paolo Corradini, Michele Cavo, Jesús San Miguel, Leyla Shune, Abdullah M Khan, Surbhi Sidana, Xavier Leleu, Salomon Manier, Brea Lipe, Katja Weisel, Joaquin Martinez-Lopez

CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma

Simon J Harrison, Cyrille Touzeau, Nicolas Kint, Katherine Li, Tamia Nguyen, Caroline Mayeur-Rousse, Marzia Rahman, Yannick Le Bris, Jeremy Er, Juliette Eugene-Lamer, Nicole M Haynes, Jessica Li, Rebecca C Abbott, Caroline Bodet-Milin, Anne Moreau, Eric Letouzé, Nikoletta Lendvai, Jordan M Schecter, William Deraedt, Arnob Banerjee, Tamar Lengil, Martin Vogel, Brad Foulk, Hao Zhao, Denis Smirnov, […]

Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial

Roberto Mina, Anne K Mylin, Hisayuki Yokoyama, Hila Magen, Winfried Alsdorf, Monique C Minnema, Leyla Shune, Iris Isufi, Simon J Harrison, Urvi A Shah, Jordan M Schecter, Martin Vogel, Nikoletta Lendvai, Katharine S Gries, Eva G Katz, Ana Slaughter, Carolina Lonardi, Jane Gilbert, Quanlin Li, William Deraedt, Octavio Costa Filho, Nitin Patel, Erika Florendo, Lionel […]